DataSolu a life sciences technology company helping pharma companies to speed up their preclinical drug development by revealing and predicting hidden heart diseases and failures.

Our technologies greatly benefit drug development, personalized drug screening approaches and toxicological validation to eliminate compounds with undesirable cardiac effects. We use the power of induced pluripotent stem cell derived cardiomyoytes (iPSC-CMs), novel stimulation methods, and artificial intelligence (AI) to expedite the time to process and predict cardiotoxicity at contract research organizations, pharma companies and universities.

We are currently working on our website. Meanwhile you can contact us by email at info@datasolu.fi.